YAP1 and cancer: This not only suggests that YAP1 is a potential novel therapeutic target for CF, but also stresses the well-known need for multiple/combinatory therapeutic strategies targeting the various defects of the mutant channel to achieve full clinical benefit of CF individuals in all aspects, including cancer propensity (33).